| Date | Title | Description |
| 26.08.2026 | Addex sells shares to extend runway into 2027 |
Founded in 2002 in Geneva, Addex Therapeutics develops small-molecule allosteric modulators for neurological disorders. The company's lead candidate, dipraglurant, targets brain injury recovery, including after stroke and traumatic brain i... |
| 08.01.2026 | Significant Advances in Pharmaceutical Pipelines for Underserved Diseases |
Oculis Holding AG has announced that its drug candidate Privosegtor was granted breakthrough therapy designation by the FDA for the treatment of optic neuritis (ON), a rare neuro‑ophthalmic condition. This approval expedites the review of ... |
| 02.07.2025 | Addex Therapeutics leads Stalicla’s CHF 2 million round |
STALICLA SA, a Geneva-based clinical-stage biotech company pioneering precision medicine for neurodevelopmental and neuropsychiatric disorders (NND). The company has established a clinically validated neuro precision development platform t... |
| 30.06.2025 | Stalicla Secures CHF 2M Financing | Stalicla, a Geneva, Switzerland-based clinical-stage biotech company developing precision medicine for neurodevelopmental and neuropsychiatric disorders, raised CHF 2M in funding.
The round was led by Addex Therapeutics.
The company intends... |
| 19.06.2025 | Addex Therapeutics Reports Q1 2025 Financial Results and Provides Corporate Update | Strong cash position of CHF2.8 million at end of Q1 2025
GABAB PAM chronic cough candidate demonstrated robust anti-tussive activity in disease models
Regained rights to our phase 2 mGlu2 PAM asset, ADX71149 Indivior advanced GABAB PAM Subs... |
| 25.04.2025 | Addex Reports Full Year 2024 Financial Results and Provides Corporate Update | Launched Neurosterix with Perceptive Advisors, raising USD 65 million in Series A to advance preclinical portfolio Indivior selected GABAB PAM drug candidate and started IND enabling studies for development in substance use disorders Addex ... |
| 22.11.2024 | Addex Reports Third Quarter 2024 Financial Results and Provides Corporate Update | Indivior selected GABA B PAM drug candidate for development in substance use disorders (SUD) and starts IND enabling studies
Ad Hoc Announcement Pursuant to Art. 53 LR
Geneva, Switzerland, November 22, 2024 - Addex Therapeutics (SIX/NASDAQ:... |
| 22.11.2024 | Addex Reports Third Quarter 2024 Financial Results and Provides Corporate Update | Indivior selected GABA B PAM drug candidate for development in substance use disorders (SUD) and starts IND enabling studies
Ad Hoc Announcement Pursuant to Art. 53 LR
Geneva, Switzerland, November 22, 2024 - Addex Therapeutics (SIX/NASDAQ:... |
| 11.11.2024 | Addex Provisional 2024 Third Quarter Results Showed Net Loss Compared to Second Quarter 2024 | Nine-month Results Remain On Track for Net Profit
Ad Hoc Announcement Pursuant to Art. 53 LR
Geneva, Switzerland, November 11, 2024 - Addex Therapeutics (SIX/NASDAQ: ADXN), a clinical-stage biopharmaceutical company focused on developing a ... |
| 11.11.2024 | Addex Provisional 2024 Third Quarter Results Showed Net Loss Compared to Second Quarter 2024 | Nine-month Results Remain On Track for Net Profit
Ad Hoc Announcement Pursuant to Art. 53 LR
Geneva, Switzerland, November 11, 2024 - Addex Therapeutics (SIX/NASDAQ: ADXN), a clinical-stage biopharmaceutical company focused on developing a ... |
| 30.09.2024 | Addex Therapeutics Reports 2024 Half Year and Second Quarter Financial Results and Provides Corporate Update | Launched Neurosterix with Perceptive Advisors to accelerate the development of M4PAM for schizophrenia Indivior selected GABA B PAM drug candidate for development in substance use disorders Addex selected independent GABAB PAM drug candidat... |
| 30.09.2024 | Addex Therapeutics Reports 2024 Half Year and Second Quarter Financial Results and Provides Corporate Update | Launched Neurosterix with Perceptive Advisors to accelerate the development of M4PAM for schizophreniaIndivior selected GABA B PAM drug candidate for development in substance use disordersAddex selected independent GABAB PAM drug candidate ... |
| 19.09.2024 | Addex Provisional 2024 Half-Year and Second Quarter Result increased from a Net loss to a Net Profit | Ad Hoc Announcement Pursuant to Art. 53 LR
Geneva, Switzerland, September 19, 2024 - Addex Therapeutics (SIX/NASDAQ: ADXN), a clinical-stage biopharmaceutical company focused on developing a portfolio of novel small molecule allosteric modu... |
| 04.09.2024 | Addex to Participate in the H.C. Wainwright 26th Annual Global Investment Conference | Geneva, Switzerland, September 4, 2024 - Addex Therapeutics (SIX/NASDAQ: ADXN), a clinical-stage biopharmaceutical company focused on developing a portfolio of novel small molecule allosteric modulators for neurological disorders, announced... |
| 04.09.2024 | Addex to Participate in the H.C. Wainwright 26th Annual Global Investment Conference | Geneva, Switzerland, September 4, 2024 - Addex Therapeutics (SIX/NASDAQ: ADXN), a clinical-stage biopharmaceutical company focused on developing a portfolio of novel small molecule allosteric modulators for neurological disorders, announced... |
| 29.08.2024 | Navigating the Turbulent Waters of Indivior: A Tale of Collaboration and Controversy | In the ever-evolving landscape of biopharmaceuticals, partnerships can be a double-edged sword. Addex Therapeutics and Indivior PLC recently announced a significant step in their collaboration, focusing on the development of GABAB positive ... |
| 28.08.2024 | Addex collaboration with Indivior enters next stage |
Addex Therapeutics SA, a clinical-stage biopharmaceutical company focused on developing a portfolio of novel small molecule allosteric modulators for neurological disorders, and Indivior PLC announced the selection of clinical candidates f... |
| 27.08.2024 | Addex and Indivior Select Clinical Candidates from GABAB Positive Allosteric Modulator Research Collaboration | Ad Hoc Announcement Pursuant to Art. 53 LR
Geneva, Switzerland, August 27, 2024 - Addex Therapeutics (SIX/NASDAQ: ADXN), a clinical-stage biopharmaceutical company focused on developing a portfolio of novel small molecule allosteric modulat... |
| 22.07.2024 | Addex’s Partner Discontinues ADX71149 development in Epilepsy | Ad Hoc Announcement Pursuant to Art. 53 LR
Geneva, Switzerland, July 22, 2024 - Addex Therapeutics (SIX and Nasdaq: ADXN), a clinical-stage biopharmaceutical company focused on developing a portfolio of novel small molecule allosteric modul... |
| 22.07.2024 | Addex’s Partner Discontinues ADX71149 development in Epilepsy | Ad Hoc Announcement Pursuant to Art. 53 LR
Geneva, Switzerland, July 22, 2024 - Addex Therapeutics (SIX and Nasdaq: ADXN), a clinical-stage biopharmaceutical company focused on developing a portfolio of novel small molecule allosteric modul... |
| 12.07.2024 | Addex To Present at the Thirteenth London International Cough Symposium (13th LICS) | Geneva, Switzerland, July 12, 2024 - Addex Therapeutics (SIX: ADXN and Nasdaq: ADXN), a clinical-stage biopharmaceutical company focused on developing a portfolio of novel small molecule allosteric modulators for neurological disorders, ann... |
| 06.06.2024 | Addex Therapeutics Reports Q1 2024 Financial Results and Provides Corporate Update | ● GABAB PAM: Selection of drug candidates under Indivior collaboration expected by end of Q2 2024.
Ad Hoc Announcement Pursuant to Art. 53 LR
Geneva, Switzerland, June 6, 2024 - Addex Therapeutics (SIX and Nasdaq: ADXN), a clinical-stage bi... |
| 05.06.2024 | Addex Convenes Annual General Meeting 2024 | Ad Hoc Announcement Pursuant to Art. 53 LR
Geneva, Switzerland, June 5, 2024 - Addex Therapeutics (SIX: ADXN and Nasdaq: ADXN), a clinical-stage biopharmaceutical company focused on developing a portfolio of novel small molecule allosteric ... |
| 01.05.2024 | Triumphs and a setback in the biotech sector |
The successful advancement of CDR-Life Inc.’s Phase 1 study with BI 771716, its therapeutic candidate in partnership with Boehringer Ingelheim (BI) for the treatment of geographic atrophy (GA), has triggered a milestone payment to the star... |
| 29.04.2024 | Addex Provides Update on ADX71149 Phase 2 Epilepsy Study | Ad Hoc Announcement Pursuant to Art. 53 LR
Geneva, Switzerland, April 29, 2024 - Addex Therapeutics (SIX and Nasdaq: ADXN), a clinical-stage biopharmaceutical company focused on developing a portfolio of novel small molecule allosteric modu... |
| 19.04.2024 | Addex to Present at the Swiss Biotech Day 2024 | Geneva, Switzerland, April 19, 2024 - Addex Therapeutics (SIX and Nasdaq: ADXN), a clinical-stage pharmaceutical company pioneering allosteric modulation-based drug development, announced today that CEO, Tim Dyer, will present at the Swiss ... |
| 18.04.2024 | Addex Therapeutics Reports Full Year 2023 Financial Results and Provides Corporate Update | Top-line data from ADX71149 Phase 2 epilepsy study expected by mid-May 2024 Launched Neurosterix with Perceptive Advisors, raising USD 63 million in Series A to accelerate development of preclinical portfolio Received CHF 5 million upfront ... |
| 11.04.2024 | Addex Therapeutics to Release Full-Year 2023 Financial Results and Host Conference Call on April 18, 2024 | Geneva, Switzerland, April 11, 2024 – Addex Therapeutics (SIX and Nasdaq: ADXN), a clinical-stage pharmaceutical company pioneering allosteric modulation-based drug development, today announced that it will issue its Full-Year 2023 Financia... |
| 03.04.2024 | Addex spin-off launched with USD63 million investment |
Addex Therapeutics is a clinical-stage biopharmaceutical company focused on developing a portfolio of novel small molecule allosteric modulators for neurological disorders. Today the company announced that it will contribute a portfolio of... |
| 14.03.2024 | Addex to Present at the Bio-Europe Spring 2024 Conference | - |
| 14.03.2024 | Addex to Present at the Bio-Europe Spring 2024 Conference | Geneva, Switzerland, March 14, 2024 – Addex Therapeutics (SIX: ADXN), a clinical-stage pharmaceutical company pioneering allosteric modulation-based drug discovery and development, announced today that CEO, Tim Dyer, will present at the Bio... |
| 05.01.2024 | Addex to Present at Biotech Showcase™ 2024 | CEO to provide update on allosteric modulator pipeline clinical and preclinical development
Geneva, Switzerland, January 5, 2024 - Addex Therapeutics (SIX and Nasdaq: ADXN), a clinical-stage pharmaceutical company pioneering allosteric modu... |
| 23.11.2023 | Addex Therapeutics to Release Third Quarter 2023 Financial Results and Host Conference Call on November 29, 2023 | Geneva, Switzerland, November 23, 2023 - Addex Therapeutics (SIX and Nasdaq: ADXN), a clinical-stage pharmaceutical company pioneering allosteric modulation-based drug discovery and development, today announced that that it will issue its T... |
| 15.08.2023 | Spexis and Addex attract new funds | |
| 05.04.2023 | Addex Completes $5.0 Million Equity Financing | - |
| 05.04.2023 | Addex Completes $5.0 Million Equity Financing | Proceeds to advance allosteric modulator therapeutic pipeline
Ad Hoc Announcement Pursuant to Art. 53 LR
Geneva, Switzerland, April 5, 2023 – Addex Therapeutics Ltd ADXN, a clinical-stage pharmaceutical company pioneering allosteric modulat... |
| 03.04.2023 | Addex Raises $5.0 Million in Equity Financing | /EIN News/ -- Ad Hoc Announcement Pursuant to Art. 53 LR
Geneva, Switzerland, April 3, 2023 - Addex Therapeutics Ltd (SIX: ADXN and Nasdaq: ADXN), a clinical-stage pharmaceutical company pioneering allosteric modulation-based drug discovery... |
| 03.04.2023 | Addex Raises $5.0 Million in Equity Financing | - |
| 14.03.2023 | The delisting dilemma: Why do so many biotechs face being kicked off the Nasdaq? | The latest fear stalking biotech boardrooms isn’t a trial fail or an underwhelming funding haul, it’s the postman delivering a letter from the Nasdaq warning that the company’s stock faces delisting from the stock exchange.
It seems to be a... |
| 20.09.2022 | Addex to Present at the Sachs Associates 22nd Annual Biotech in Europe Forum & Baader Investment Conference | Geneva, Switzerland, September 20, 2022 - Addex Therapeutics (SIX and Nasdaq: ADXN), a clinical-stage pharmaceutical company pioneering allosteric modulation-based drug discovery and development, announced today that CEO, Tim Dyer will pres... |
| 26.07.2022 | Addex Completes $4.2 Million Equity Financing | Ad Hoc Announcement Pursuant to Art. 53 LR
Geneva, Switzerland, July 26, 2022 – Addex Therapeutics Ltd (SIX: ADXN and Nasdaq: ADXN), a clinical-stage pharmaceutical company pioneering allosteric modulation-based drug discovery and developme... |
| 22.07.2022 | Addex Raises $4.2 million in Equity Financing | Ad Hoc Announcement Pursuant to Art. 53 LR
Geneva, Switzerland, July 22, 2022 – Addex Therapeutics Ltd (SIX: ADXN and Nasdaq: ADXN), a clinical-stage pharmaceutical company pioneering allosteric modulation-based drug discovery and developme... |
| 22.07.2022 | Addex raised $4.2 million in equity funding | |
| 21.07.2022 | Addex Completes Reduction in Nominal Value of Shares | Ad Hoc Announcement Pursuant to Art. 53 LR
Geneva, Switzerland, July 21, 2022 - Addex Therapeutics Ltd (SIX: ADXN, Nasdaq: ADXN), a clinical-stage pharmaceutical company pioneering allosteric modulation-based drug discovery and development,... |
| 21.07.2022 | Addex Provides Corporate Update and Financial Guidance | Ad Hoc Announcement Pursuant to Art. 53 LR
Geneva, Switzerland, July 21, 2022 - Addex Therapeutics Ltd (SIX: ADXN, Nasdaq: ADXN), a clinical-stage pharmaceutical company pioneering allosteric modulation-based drug discovery and development,... |
| 17.06.2022 | Addex Terminates Dipraglurant Phase 2b/3 Study in Patients with Dyskinesia Associated with Parkinson’s Disease due to Slow Recruitment Rate | COVID-19 related challenges negatively impacted patient recruitment
Ad Hoc Announcement Pursuant to Art. 53 LR
Geneva, Switzerland, June 17, 2022 - Addex Therapeutics Ltd (SIX: ADXN, Nasdaq: ADXN), a clinical-stage pharmaceutical company pi... |
| 27.05.2022 | Addex Provides Update on Dipraglurant Blepharospasm Phase 2 Feasibility Clinical Study | Ad Hoc Announcement Pursuant to Art. 53 LR
Geneva, Switzerland, May 27, 2022 - Addex Therapeutics Ltd (SIX: ADXN, Nasdaq: ADXN), a clinical-stage pharmaceutical company pioneering allosteric modulation-based drug discovery and development, ... |
| 19.05.2022 | Addex Announces Participation in the H.C. Wainwright Global Investment Conference | Geneva, Switzerland, May 19, 2022 - Addex Therapeutics Ltd (SIX: ADXN, Nasdaq: ADXN), a clinical-stage pharmaceutical company pioneering allosteric modulation-based drug discovery and development, announced today that CEO, Tim Dyer, will be... |
| 13.05.2022 | Addex Announces Participation in the 22nd Bio€quity Europe Conference | Geneva, Switzerland, May 13, 2022 - Addex Therapeutics Ltd (SIX: ADXN, Nasdaq: ADXN), a clinical-stage pharmaceutical company pioneering allosteric modulation-based drug discovery and development, announced today that CEO, Tim Dyer, and Dr.... |
| 10.05.2022 | Addex Shareholders Approve All Resolutions at Annual General Meeting | Ad Hoc Announcement Pursuant to Art. 53 LR
Geneva, Switzerland, May 10, 2022 – Addex Therapeutics (SIX: ADXN), a clinical-stage pharmaceutical company pioneering allosteric modulation-based drug discovery and development, announced today th... |
| 05.05.2022 | Addex Reports Q1 2022 Financial Results | CHF14.9M ($16.1M) of cash and cash equivalents at March 31, 2022
Dipraglurant Phase 2 blepharospasm clinical trial on track to report data in Q2 2022
Phase 2b/3 dipraglurant study in dyskinesia associated with Parkinson’s disease expected t... |
| 28.04.2022 | Addex to Present at the Swiss Biotech Day 2022 | Geneva, Switzerland, April 28, 2022 - Addex Therapeutics Ltd (SIX: ADXN, Nasdaq: ADXN), a clinical-stage pharmaceutical company pioneering allosteric modulation-based drug discovery and development, announced today that CEO, Tim Dyer, will ... |
| 25.04.2022 | Addex to Present at the B. Riley Securities Neuro & Ophthalmology Virtual Investor Conference | Geneva, Switzerland, April 25, 2022 - Addex Therapeutics Ltd (SIX: ADXN, Nasdaq: ADXN), a clinical-stage pharmaceutical company pioneering allosteric modulation-based drug discovery and development, announced today that CEO, Tim Dyer, will ... |
| 13.04.2022 | Addex Therapeutics Completes Patient Enrollment for Dipraglurant Blepharospasm Phase 2 Clinical Study | Top-line Data Scheduled to Report in Q2 2022
Ad Hoc Announcement Pursuant to Art. 53 LR
Geneva, Switzerland, April 13, 2022 - Addex Therapeutics Ltd (SIX: ADXN, Nasdaq: ADXN), a clinical-stage pharmaceutical company pioneering allosteric mo... |
| 06.04.2022 | Addex Expands Pipeline with Selective M4 Positive Allosteric Modulator Program for the Treatment of Schizophrenia & Other Psychotic Disorders | New Series of Potent and Selective Compounds Identified Using Proprietary Allosteric Modulator Screening Platform
Ad Hoc Announcement Pursuant to Art. 53 LR
Geneva, Switzerland, April 6, 2022 - Addex Therapeutics (SIX: ADXN and Nasdaq: ADXN... |
| 31.03.2022 | Addex Convenes Annual General Meeting 2022 | Ad Hoc Announcement Pursuant to Art. 53 LR
Geneva, Switzerland, March 31, 2022 - Addex Therapeutics (SIX: ADXN and Nasdaq: ADXN), a clinical-stage pharmaceutical company pioneering allosteric modulation-based drug discovery and development,... |
| 24.03.2022 | Addex to Present at the Bio-Europe Spring 2022 and Maxim Group – 2022 Virtual Growth Conferences | Geneva, Switzerland, March 24, 2022 - Addex Therapeutics (SIX: ADXN and Nasdaq: ADXN), a clinical-stage pharmaceutical company pioneering allosteric modulation-based drug discovery and development, announced today that CEO, Tim Dyer, will p... |
| 10.03.2022 | Addex Reports Full Year 2021 Financial Results and Provides Corporate Update | CHF20.5M ($22.5M) of cash and cash equivalents at December 31, 2021
Dipraglurant Phase 2 blepharospasm clinical trial on track to report data in Q2 2022
Phase 2b/3 dipraglurant study in dyskinesia associated with Parkinson’s disease expecte... |
| 07.03.2022 | Addex Therapeutics to Release Full-Year 2021 Financial Results and Host Conference Call on March 10, 2022 | Geneva, Switzerland, March 7, 2022 – Addex Therapeutics (SIX: ADXN, Nasdaq: ADXN), a clinical-stage pharmaceutical company pioneering allosteric modulation-based drug discovery and development, announced today that it will issue its full-ye... |
| 03.02.2022 | Addex Increases Issued Share Capital to Create Treasury Shares | Ad Hoc Announcement Pursuant to Art. 53 LR
Geneva, Switzerland, February 3, 2022 - Addex Therapeutics (SIX: ADXN and Nasdaq: ADXN), a clinical-stage pharmaceutical company pioneering allosteric modulation-based drug discovery and developmen... |
| 11.01.2022 | Addex to Present at the Swiss Equities Baader Virtual Conference | Geneva, Switzerland, January 11, 2022 - Addex Therapeutics (SIX: ADXN and Nasdaq: ADXN), a clinical-stage pharmaceutical company pioneering allosteric modulation-based drug discovery and development, announced today that CEO, Tim Dyer, will... |
| 06.01.2022 | Addex to Present at the H.C. Wainwright BIOCONNECT Virtual Conference | Geneva, Switzerland, January 6 2022 - Addex Therapeutics (SIX: ADXN and Nasdaq: ADXN), a clinical-stage pharmaceutical company pioneering allosteric modulation-based drug discovery and development, announced today that CEO, Tim Dyer, will p... |
| 20.12.2021 | Addex Therapeutics : Raises $10.0 Million in Equity Financing - Form 6-K | Addex Raises $10.0 Million in Equity Financing
Ad Hoc Announcement Pursuant to Art. 53 LR
Geneva, Switzerland, December 17, 2021 - Addex Therapeutics Ltd (SIX: ADXN and Nasdaq: ADXN), a clinical-stage pharmaceutical company pioneering allos... |
| 17.12.2021 | Addex Raises $10.0 Million in Equity Financing | (MORE TO FOLLOW) Dow Jones Newswires
December 17, 2021 01:00 ET (06:00 GMT) |
| 17.12.2021 | Addex Raises $10.0 Million in Equity Financing | Ad Hoc Announcement Pursuant to Art. 53 LR
Geneva, Switzerland, December 17, 2021 – Addex Therapeutics Ltd (SIX: ADXN and Nasdaq: ADXN), a clinical-stage pharmaceutical company pioneering allosteric modulation-based drug discovery and devel... |
| 15.12.2021 | Addex Provides Year End Pipeline Development Update | Ad Hoc Announcement Pursuant to Art. 53 LR
Geneva, Switzerland, 15 December 2021 - Addex Therapeutics (SIX: ADXN and Nasdaq: ADXN), a clinical-stage pharmaceutical company pioneering allosteric modulation-based drug discovery and developmen... |
| 18.11.2021 | Addex to Present at the Virtual German Equity Forum | Geneva, Switzerland, November 18, 2021 - Addex Therapeutics (SIX: ADXN, Nasdaq: ADXN), a clinical-stage pharmaceutical company pioneering allosteric modulation-based drug discovery and development, announced today that CEO, Tim Dyer, and He... |
| 15.11.2021 | Addex Strategic Partner Successfully Completes Phase 1 in Japan with ADX71149 | Setting Up Global Expansion of Phase 2 Clinical Evaluation in Epilepsy Patients
Ad Hoc Announcement Pursuant to Art. 53 LR
Geneva, Switzerland, November 15, 2021 – Addex Therapeutics (SIX: ADXN and Nasdaq: ADXN), a clinical-stage pharmaceut... |
| 15.11.2021 | Addex to Present at the H.C. Wainwright 7th Annual Israel Virtual Conference | Geneva, Switzerland, November 15, 2021 - Addex Therapeutics (SIX: ADXN, Nasdaq: ADXN), a clinical-stage pharmaceutical company pioneering allosteric modulation-based drug discovery and development, announced today that CEO, Tim Dyer, will p... |
| 04.11.2021 | Addex Reports Q3 2021 Financial Results and Provides Corporate Update | CHF15.5M ($16.6M) of cash and cash equivalents at September 30, 2021Cash used in Q3 2021 of CHF2.6MDipraglurant Phase 2 blepharospasm clinical trial InitiatedPhase 2b/3 dipraglurant study in dyskinesia associated with Parkinson’s disease on... |
| 01.11.2021 | Addex Therapeutics to Release Q3 2021 Financial Results and Host Conference Call on November 4, 2021 | Geneva, Switzerland, November 1, 2021 – Addex Therapeutics (SIX: ADXN, Nasdaq: ADXN), a clinical-stage pharmaceutical company pioneering allosteric modulation-based drug discovery and development, announced today that it will issue its Q3 2... |
| 06.10.2021 | Addex to Present at the Investors’ Day hosted by Voxia Communication | Geneva, Switzerland, October 6, 2021 - Addex Therapeutics (SIX: ADXN, Nasdaq: ADXN), a clinical-stage pharmaceutical company pioneering allosteric modulation-based drug discovery and development, announced today that CEO, Tim Dyer, will pre... |
| 29.06.2021 | Addex Therapeutics Initiates Pivotal Phase 2b/3 Study with Dipraglurant for Dyskinesia Associated with Parkinson's Disease | Geneva, Switzerland, June 29, 2021 - Addex Therapeutics Ltd (SIX: ADXN, Nasdaq: ADXN), a clinical-stage pharmaceutical company pioneering allosteric modulation-based drug discovery and development, announced today that screening of patients... |
| 09.03.2021 | Addex Therapeutics to Release Full-Year 2020 Financial Results and Host Conference Call on March 11, 2021 | Geneva, Switzerland, March 9, 2021 – Addex Therapeutics (SIX:ADXN), a clinical-stage pharmaceutical company pioneering allosteric modulation-based drug discovery and development, announced today that it will issue its full-year 2020 financi... |
| 16.02.2021 | Addex GABAB Positive Allosteric Modulator Demonstrates Promise in Alcohol Use Disorder | Review from Linköping University Published in Alcohol and Alcoholism Journal
Geneva, Switzerland, February 16, 2021 – Addex Therapeutics (SIX: ADXN and Nasdaq: ADXN), a clinical-stage pharmaceutical company pioneering allosteric modulation-... |
| 03.11.2020 | Addex Therapeutics : Quarter 3 Report | Allosteric Modulators for Human Health
Quarter 3 2020
Interim Report
Quarter 3 Report│ Interim Condensed Consolidated Financial Statements
Contents
p.3 Interim Condensed Consolidated Financial Statements
p.19 Financial Review
2
Quarter 3 Re... |
| 03.11.2020 | ADDEX THERAPEUTICS LTD
Addex Therapeutics : Quarter 3 Report | Allosteric Modulators for Human Health
Quarter 3 2020
Interim Report
Quarter 3 Report│ Interim Condensed Consolidated Financial Statements
Contents
p.3 Interim Condensed Consolidated Financial Statements
p.19 Financial Review
2
Quarter 3 Re... |
| 20.09.2018 | Addex Receives £1.2 million Funding from the Wellcome Trust | |
| 02.07.2018 | Appello Pharmaceuticals nets $10.5 million in Series A funding for Parkinson’s drugs | The company’s rationale for the drugs is that the current standard of care, dopamine replacement therapy, relieves some of the motor symptoms of Parkinson’s, but also causes involuntary and uncontrollable movements called dyskinesia, becomi... |
| 05.03.2018 | Addex Secures Investor Commitment for CHF40 million Capital Increase | |
| 03.01.2018 | Two biotech startups receive milestone payments | |
| 18.06.2012 | Addex to Present Phase 2a Dipraglurant Data at Movement Disorder Society’s International Congress | Geneva, Switzerland, 18 June 2012 – Addex Therapeutics (SIX:ADXN), a leading company pioneering allosteric modulation-based drug discovery and development, announced today that positive data from a recently completed Phase 2a study with dip... |
| 16.04.2012 | Addex Reports Positive Preclinical Data for GABA-BR PAM Oral Small Molecule in Overactive Bladder | Geneva, Switzerland, 16 April 2012 – Addex Therapeutics (SIX:ADXN), a leading organization pioneering allosteric modulation-based drug discovery and development, announced today positive data from studies of its lead GABA-B receptor (GABA-B... |
| - | Appello Pharmaceuticals nets $10.5 million in Series A funding for Parkinson’s drugs | A firm developing a drug class licensed from Vanderbilt University for Parkinson’s disease has secured more than $10 million in Series A financing.
Nashville, Tennessee-based Appello Pharmaceuticals said last week it had raised $10.5 millio... |
